E-ISSN 2231-3206 | ISSN 2320-4672
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research

Online Publishing Date:
25 / 10 / 2017

 


Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis

Rajashekar Y R, Shobha S N.


Abstract
Background: Antiallergic drugs are widely prescribed in allergic rhinitis (AR). Antihistamines and antileukotrienes are effective only in providing symptomatic relief of allergic symptoms, often used as fixed dose combinations (FDC) of both. Controversial reports regarding their efficacy in AR, when used alone or in their combined preparations, prompted the present study.

Aims and Objectives: The aim of this study was to compare the anti-allergic effect of ebastine, montelukast, and their FDC on the subjective nasal and extranasal symptoms in mild-to-moderate persistent AR (PAR) patients.

Materials and Methods: Mild-to-moderate PAR patients divided into three groups to receive drugs ebastine, montelukast, and their combined preparation for 3 weeks. Their efficacy was measured by total five nasal symptoms scoring system, AM, and PM symptom scores. The treatment was withdrawn in the last week, to assess the persisting anti-allergic action of treatment drugs.

Results: When compared to baseline values, all the treatment groups showed a significant decrease in the total mean score of allergic symptoms. Ebastine and its combination with montelukast significantly decreased both AM and PM mean scores, but montelukast did only for PM mean score. Among three compared groups, ebastine and its combined preparation with montelukast were found significant in reducing total and AM symptoms.

Conclusion: All 3 groups showed anti-allergic effects in a variable manner. Montelukast controlled daytime symptoms better. Ebastine and its combination with montelukast controlled allergic symptoms to a similar extent.

Key words: Ebastine; Montelukast; Allergic Rhinitis; Total Five Nasal Symptoms Scoring


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Rajashekar Y R
Articles by Shobha S N
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Rajashekar Y R, Shobha S N. Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis. Natl J Physiol Pharm Pharmacol. 2018; 8(3): 319-324. doi:10.5455/njppp.2018.8.0935522092017

Web Style

Rajashekar Y R, Shobha S N. Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis. https://www.njppp.com/?mno=277934 [Access: March 14, 2024]. doi:10.5455/njppp.2018.8.0935522092017

AMA (American Medical Association) Style

Rajashekar Y R, Shobha S N. Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis. Natl J Physiol Pharm Pharmacol. 2018; 8(3): 319-324. doi:10.5455/njppp.2018.8.0935522092017


Vancouver/ICMJE Style

Rajashekar Y R, Shobha S N. Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis. Natl J Physiol Pharm Pharmacol. (2018), [cited March 14, 2024]; 8(3): 319-324. doi:10.5455/njppp.2018.8.0935522092017


Harvard Style

Rajashekar Y R, Shobha S N (2018) Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis. Natl J Physiol Pharm Pharmacol, 8 (3), 319-324. doi:10.5455/njppp.2018.8.0935522092017


Turabian Style

Rajashekar Y R, Shobha S N. 2018. Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis. National Journal of Physiology, Pharmacy and Pharmacology, 8 (3), 319-324. doi:10.5455/njppp.2018.8.0935522092017


Chicago Style

Rajashekar Y R, Shobha S N. "Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis." National Journal of Physiology, Pharmacy and Pharmacology 8 (2018), 319-324. doi:10.5455/njppp.2018.8.0935522092017


MLA (The Modern Language Association) Style

Rajashekar Y R, Shobha S N. "Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis." National Journal of Physiology, Pharmacy and Pharmacology 8.3 (2018), 319-324. Print. doi:10.5455/njppp.2018.8.0935522092017


APA (American Psychological Association) Style

Rajashekar Y R, Shobha S N (2018) Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis. National Journal of Physiology, Pharmacy and Pharmacology, 8 (3), 319-324. doi:10.5455/njppp.2018.8.0935522092017


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

  National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272